Abstracts tagged "Biomarkers"

Abstract Number: 1484 • 2018 ACR/ARHP Annual Meeting
Value of Anti-RA33 Isotypes in an European Rheumatoid Arthritis Patient Cohort
Maresa Grundhuber¹, Daniela Sieghart², Günter Steiner², Maryam Poorafshar³ and Sascha Swiniarski¹, ¹Thermo Fisher Scientific, Freiburg, Germany, Freiburg, Germany, ²Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Austria, Vienna, Austria, ³Thermo Fisher Scientific, Uppsala, Sweden, Uppsala, Sweden
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) leading to effective treatment is essential to improve prognosis and to prevent disease progression. Anti-cyclic citrullinated peptide (CCP)…
Abstract Number: 2020 • 2018 ACR/ARHP Annual Meeting
Novel Serum Biomarkers Monitor Disease Progression and Response to Change in Corticosteroid Therapy in Children with Juvenile Dermatomyositis
Lauren M. Pachman^1,2, Shefa Tawalbeh³, Gabrielle A. Morgan⁴, Wilfredo Marin⁴, Laurie Conklin⁵, Yetrib Hathout⁶ and Eric Hoffman³, ¹Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ²Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Binghampton University, Binghampton, NY, ⁴Cure JM Program of Excellence in Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁵Children’s National Medical Center, Washington, DC, ⁶Pharmaceutical Sciences, Binghampton University, Binghampton, NY
Novel Serum Biomarkers Monitor Disease Progression and Response to Change in Corticosteroid Therapy in Children with Juvenile Dermatomyositis Background/Purpose: Juvenile Dermatomyositis (JDM) is a complex autoimmune…
Abstract Number: 2899 • 2018 ACR/ARHP Annual Meeting
Sustained Drug-Free Remission in Early RA Following Methotrexate-Based Strategy: Role of the JAK-STAT Pathway
Xavier M Teitsma¹, Johannes W. G. Jacobs², Arno N Concepcion³, Attila Pethö-Schramm⁴, Michelle EA Borm⁵, Jacob van Laar¹, Johannes W. J. Bijlsma⁶ and Floris PJG Lafeber¹, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ²Rheumatolgy & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴F. Hoffmann-La Roche, Basel, Switzerland, ⁵Roche Nederland BV, Woerden, Netherlands, ⁶Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: We previously identified several co-expressed genes associated with achieving sustained drug-free remission (sDFR) following a methotrexate (MTX)-based strategy in early rheumatoid arthritis (RA).1 The…
Abstract Number: 739 • 2018 ACR/ARHP Annual Meeting
Urine and Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Differentially Correlates with Renal and Non-Renal Systemic Lupus Erythematosus (SLE): A Prospective, Case-Control Study
Yair Molad^1,2, Mohammad Egbaria³, Ariela Dortort-Lazar^4,5, Elisheva Pokroy-Shapira^3,5, Shirly Oren⁴, Yonatan Edel^3,5 and Vitaly Kliminski^5,6, ¹Rheumatology Unit, Rabin Medical Center - Beilinson Campus, Petah-Tiqva, Israel, ²Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel, ³Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, ⁴Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel, ⁵Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁶Laboratory of Inflammation Research, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva, Israel
Background/Purpose: Elevated levels of sTREM-1 have been previously found in patients with SLE. A prospective, case-control, longitudinal study aimed to assess the value of urinary…
Abstract Number: 1089 • 2018 ACR/ARHP Annual Meeting
Commensal Gut Bacteria of Anti-Ro Positive Mothers of Children with Neonatal Lupus in Aggregate Resemble Healthy Subjects without Overt Dysbiosis of Abundance of Microorganisms
Robert M. Clancy¹, Carl Langefeld², Hannah C. Ainsworth³, H. Michael Belmont¹, Martin Blaser⁴, Peter M. Izmirly⁵, Corey Lacher¹, Miranda C Marion⁶, Mala Masson¹, Gregg Silverman⁷ and Jill P. Buyon¹, ¹NYU School of Medicine, New York, NY, ²Wake Forest School of Medicine, Winston-Salem, NC, ³Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁴Director of the NYU Human Microbiome Program, NYU School of Medicine, New York, NY, ⁵Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ⁶Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, NC, ⁷Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Anti-Ro60 autoantibodies are present in asymptomatic individuals years before onset of disease. We hypothesize that differences in autoreactivity-inducing commensal abundances may drive progression to…
Abstract Number: 1492 • 2018 ACR/ARHP Annual Meeting
Methotrexate Response in Early Rheumatoid Arthritis Predicted Using a Somamer Proteomic Assay
Carol Hitchon¹, Victor Spicer¹, Nathalie Carrier², Ang Gao¹, Hani El-Gabalawy¹, John Wilkins¹ and Gilles Boire³, ¹University of Manitoba, Winnipeg, MB, Canada, ²Centre intégré universitaire de santé et de services sociaux de l'Estrie -Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ³Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Available clinical tools do not adequately identify treatment non-responders in early rheumatoid arthritis (RA) leading to delayed disease control. Tools informed by molecular phenotype…
Abstract Number: 2023 • 2018 ACR/ARHP Annual Meeting
Different Patterns of Interferon-Response-Gene Expression May Elucidate Different Pathomechanisms That Drive IFN-Response-Gene Activation in Patients with Presumed IFN-Mediated Autoinflammatory Diseases
Adriana Almeida de Jesus¹, Yanfeng Hou², Louise Malle³, Scott Canna⁴, Gina A. Montealegre Sanchez¹, Hanna Kim⁵, Rachel VanTries¹, Seza Ozen⁶, Samantha Dill⁷, Dawn C. Chapelle⁷, Bernadette Marrero¹, Yan Huang¹, Angelique Biancotto⁸ and Raphaela Goldbach-Mansky¹, ¹Translational Autoinflammatory Disease Section (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ²Department of Rheumatology, Shandong Provincial Qianfoshan Hospital, Shandong University, Shandong, China, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴RK Mellon Institute for Pediatric Research, University of Pittsburgh/Children's Hospital of Pittsburgh of UPMC, Pittsburrgh, PA, ⁵Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, ⁶Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, ⁷Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ⁸Center for Human Immunology Autoimmunity and Inflammation (CHI), NIAID, NIH, Bethesda, MD
Background/Purpose: Many infants and children with early-onset autoinflammatory diseases are mutation-negative for genetically known autoinflammatory diseases. Recent data suggest a role for Type-I interferon dysregulation…
Abstract Number: 2904 • 2018 ACR/ARHP Annual Meeting
Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients and Healthy Controls
Ralf G. Thiele¹, Yahui Grace Chiu², Nelson Huertas³, Dongge Li⁴, Changyong Feng⁵, Sharon Moorehead⁶, Cristy Bell⁷ and Christopher T. Ritchlin⁸, ¹Division of Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, ³Department of Medicine, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ⁵Statistics, University of Rochester, Rochester, NY, ⁶Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁷Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁸Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY
Background/Purpose: The events that underlie the transition from psoriasis (Ps) to psoriatic arthritis (PsA) are not well understood, although up to 30% of Ps patients…
Abstract Number: 740 • 2018 ACR/ARHP Annual Meeting
Can Monocyte Chemo-Attractant Protein-1differentiate Different Histological Classes in Lupus Nephritis?
Varun Dhir¹, Ranjeeth Kumar Gone², Amit Sandhu³, Aman Sharma⁴, Shefali Sharma⁵, Ritambhra Nada², Sanjay Jain⁶ and Manish Rathi⁷, ¹Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, ²Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁴Clinical Immunology and Rheumatology Services, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, ⁵Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, ⁶Postgraduate Institute of Medical Education and Research, Chandigarh, India, CHANDIGARH, India, ⁷Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Lupus Nephritis one of the commonest manifestations of SLE. Despite being the gold standard in Lupus nephritis, renal biopsy is an invasive procedure with…
Abstract Number: 1090 • 2018 ACR/ARHP Annual Meeting
Cell-Free Mitochondrial DNA As a Novel Biomarker in Systemic Lupus Erythematosus
Bhargavi Duvvuri¹, Richard Moore¹ and Christian Lood², ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: We recently described a fundamental role for mitochondrial (mt)-mediated inflammation in systemic lupus erythematosus (SLE). Briefly, mtROS promoted formation of neutrophil extracellular traps (NETs),…
Abstract Number: 1500 • 2018 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score Tracks Response to Rituximab Treatment in Rheumatoid Arthritis Patients
Nadia MT Roodenrijs¹, Maria JH de Hair¹, Gill Wheater², Mohsen Elshahaly³, Janneke Tekstra¹, Y.K. Onno Teng⁴, Floris PJG Lafeber¹, Ching Chang Hwang⁵, Xinyu Liu⁶, Eric H. Sasso⁵ and Jacob van Laar¹, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ²Department of Biochemistry, The James Cook University Hospital, Middlesbrough, UK, Middlesbrough, United Kingdom, ³Department of Rheumatology & Rehabilitation, Suez Canal University, Ismailia, Egypt, Ismailia, Egypt, ⁴Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ⁵Crescendo Bioscience, San Francisco, CA, USA, South San Francisco, CA, ⁶Crescendo Bioscience, San Francisco, CA, USA, San Francisco, CA
Background/Purpose: A multi-biomarker disease activity (MBDA) score was developed to objectively measure disease activity for patients with rheumatoid arthritis (RA).1 The MBDA score is calculated…
Abstract Number: 2026 • 2018 ACR/ARHP Annual Meeting
Calcium Crystal-Mediated Netosis in Juvenile Dermatomyositis and Anti-RNP+ Overlap Syndrome with Skin Involvement
Christian Lood¹, Gabrielle A. Morgan², Marisa Klein-Gitelman³, Megan L. Curran⁴ and Lauren M. Pachman⁵, ¹Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, ²Cure JM Program of Excellence in Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ³Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴Section of Rheumatology, Children's Hospital of Colorado, Denver, CO, ⁵Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
Background/Purpose: Neutrophils are key immune cells participating in host defense through several mechanisms, including the formation of neutrophil extracellular traps (NETs). Although beneficial from a…
Abstract Number: 2920 • 2018 ACR/ARHP Annual Meeting
Correlations of Type I Interferon Score and Interferon Induced Chemokines CXCL10 and CXCL9 with Cutaneous and Muscular Disease Activity in Juvenile Dermatomyositis
Gian Marco Moneta¹, Ivan Caiello¹, Lucilla Rava'², Silvia Rosina³, Luisa Bracci Laudiero^1,4, Angelo Ravelli^3,5, Fabrizio De Benedetti⁶ and Rebecca Nicolai⁷, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ²Epidemiology Unit, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ³University of Genova, Genova, Italy, ⁴Institute of Translational Pharmacology, CNR, Roma, Italy, ⁵Rheumatology, Giannina Gaslini Institute, Genova, Italy, ⁶IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ⁷Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Background/Purpose: Interferons (IFNs) seem to play an important role in the pathogenesis of juvenile dermatomyositis (JDM). We previously reported that expression of both type I…
Abstract Number: 776 • 2018 ACR/ARHP Annual Meeting
MMP7 and CXCL12: Two Promising Biomarkers in Lupus Nephritis
Sylvie Goletti^1,2, Séverine Nieuwland³, Frédéric A. Houssiau^2,3 and Bernard R. Lauwerys^2,3, ¹Service de Microbiologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ³Rheumatology Department, Cliniques universitaires Saint-Luc, Brussels, Belgium
Background/Purpose: Lupus nephritis (LN) is one of the most serious complications of Systemic lupus erythematosus (SLE). Early diagnosis of renal impairment, combined with a strict…
Abstract Number: 1095 • 2018 ACR/ARHP Annual Meeting
IFN Gene Expression Correlates with Frequency of Circulating Switched Memory B-Cells in Patients with Incomplete Systemic Lupus Erythematosus
Wietske Lambers¹, Geert Lanting¹, Wayel H. Abdulahad², Hendrika Bootsma², Johanna Westra² and Karina de Leeuw³, ¹Rheumatology/Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Incomplete systemic lupus erythematosus (iSLE) includes patients with typical features of SLE, who do not meet classification criteria. Still, up to 50% will develop…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].